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Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths 
worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis 
of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against 
PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treat- 
ment of GC. This review describes the chemical structure, the pharmacologic properties and the current 
knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and 
later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other 
drugs are also described. 
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Gastric cancer (GC) is the fifth most common cancer with 1,000,000 new cases in 2018 and the third leading cause 
of cancer-related deaths, with around 783,000 estimated deaths in 2018 (around 1/12 of cancer deaths globally) [1]. 
Surgery remains the main curative option for advanced GC, even if the overall 5-year survival remains very 
poor [2]. Moreover, perioperative and adjuvant chemotherapy – as well as chemoradiation – can improve patients’ 
clinical outcomes. There are several chemotherapeutic drugs for GC. The main first-line treatment for this disease 
is the combination of platinum derivatives and a fluoropyrimidine [3,4]. Taxanes and/or irinotecan are effective 
second- or third-line treatment options [5–7]. Ramucirumab and apatinib are two inhibitors that block in a different 
way the VEGF receptor 2 (VEGFR2) that both have increased survival in pretreated GC patients [8]. Recently, 
trifluridine/tipiracil (TAS-102) chemotherapy showed to increase overall survival compared with placebo as third- 
line or later therapy for advanced GC [9]. The US FDA approved in 2017 one immunotherapeutic agent targeting 
programmed death-1 (PD-1), pembrolizumab, for the treatment of patients with locally advanced or metastatic 
GC whose tumors expressed programmed death ligand-1 (PD-L1; combined positive score ≥1) as determined 
by a US FDA-approved test, after having progressed to previous treatments. Approval of the drug came from the 
results of the KEYNOTE 059 trial [10]. In addition, nivolumab, which is a human monoclonal antibody against 
PD-1, showed a survival advantage against placebo in the randomized, double-blind, placebo-controlled, Phase III 
trial ONO-4538-12, ATTRACTION-2 [11]. This trial included 49 clinical sites of the Asian population including 
Japan, South Korea and Taiwan. Median overall survival was 5.26 months in the nivolumab group and 4.14 months 
in the placebo group. Based on these results, nivolumab has been approved in Japan. In this context, avelumab, 
a drug that was FDA-approved for the treatment of urothelial carcinoma and Merkel cell carcinoma has shown 
some positive results for the treatment of GC in early-phase clinical trials and therefore thought to be investigated 
in larger clinical settings [12]. For such reasons, avelumab appears to be a valid option also for the treatment of GC 
and there are some ongoing clinical trials that are investigating its efficacy to improve the very poor prognosis of 
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this disease. The purpose of this mini-review is to recapitulate the current data available for the treatment of GC 
through avelumab therapy. Lastly, future directions will be discussed. 
 
The rationale for the use of checkpoint inhibitors in GC & gastroesophageal junction cancers 
The evasion of immune response is a hallmark for the progression and development of cancer, including tumor 
escape due to the blockade of immune checkpoint pathways [13]. Key immune checkpoints proteins such as PD- 
1, cytotoxic T-lymphocyte antigen-4, lymphocyte activation gene protein-3, indoleamine 2,3-dioxygenase, T-cell 
immunoglobulin and mucin domain-containing protein 3 are overexpressed on immune cells in patients affected 
by GC/gastroesophageal junction cancers (GEJCs) [14–16]. Noteworthy in this context is a population of T-cells 
characterized by a loss of T-cell function – and therefore called exhausted T-cells – which play a pivotal role in 
the progression of disease [17]. PD-L1, on immune and tumor cells, and its ligand PD-1, on immune cells, have 
been reported to be expressed on up to 50% of GC/GEJC neoplasms and correlated with a worse prognosis [18,19]. 
By blocking the checkpoint proteins and hence inhibitory signals, antibodies can re-establish and promote T-cells 
antitumor activity [21,22]. Moreover, several GC/GEJC tumors have been reported to have a high mutational 
burden, especially those with microsatellite instability (MSI) [23]. Tumor mutation burden has been shown to 
positively correlate with better outcome in immunotherapy-treated patients [24]. 
On the other hand, preliminary studies eliciting an immune response in GC/GEJC have been conducted: the 
Bacillus Calmette-Guerin vaccine, picibanil and polysaccharide-K treatments are some examples [25]. Moreover, it 
is currently emerging that chemotherapy might enhance cancer immunogenicity and enhance cancer vulnerability 
to immune checkpoint inhibitors in the GC/GEJC treatment scenario [26]. 
Finally, The Cancer Genome Atlas has categorized GCs in four molecular subtypes: MSI-high, Epstein–Barr 
virus-positive, genomically stable and chromosomally instable [27]. Considering this molecular classification, MSI- 
high and Epstein–Barr virus-positive are the subtypes that may most benefit to immune checkpoint inhibitors: 
MSI-high for the increased number of somatic mutations secondary to the defects in DNA mismatch repair and 
Epstein–Barr virus-positive for the alterations secondary to the presence of oncogenic viruses and higher levels of 
PD-L1 expression [28]. However, EBV-positive subgroup and MSI-high account for about the 20 and 10% of all 
GCs, respectively. 
 
Biologic 
Avelumab (Bavencio, MSB0010718C) is an IgG1 fully human anti-PD-L1 antibody, created by EMD Serono, 
a business of Merck KGaA, Darmstadt, Germany, to fight tumor cells [29]. Avelumab inhibits PD-L1/PD-1 
interaction in order to disinhibit T-cells and removes the suppression of T-cell activity, whose response can be 
assessed by evaluating the release of IFN-γ [30]. Avelumab does not modify PD-L2/PD-1 pathway permitting the 
continuity of PD-L2-arbitrated homeostasis [31]. Moreover, also the interaction of PD-L1 with a second inhibitory 
receptor, B7.1, is inhibited by avelumab; this receptor might be expressed on T-cells and antigen-presenting cells 
(APCs) [32]. By blocking the interaction between B7.1 and PD1 on T-cells and with PD-L1 on APCs within the 
lymph nodes or tumor microenvironment, avelumab might reactivate T-cells and the production of cytokines [33]. 
Furthermore, because of its native IgG1 crystallizable fragment (Fc) domain, avelumab conserves the ability to 
engage natural killer (NK) cells with the Fc-γ receptor to induce tumor-targeted antibody-dependent cell-mediated 
cytotoxicity (ADCC) in vitro [34]. 
This capacity to promote innate immune interactions against tumor cells makes avelumab exclusive among 
anti-PD-L1 or anti-PD1 antibodies in ongoing clinical trials. 
 
Structural basis of avelumab’s inhibition of PD-L1 
The crystal structure of the human PD-L1 (hPD-L1) complexed with the single-chain Fv fragment (scFv) of 
avelumab was established at a resolution of 3.2 A˚ by molecular replacement. The overall structure of the complex 
shows that avelumab uses both light chain (VL) and heavy chain (VH) to tether the N-terminal domain (IgV) 
of PD-L1 on the side. The interaction with hPD-L1 includes five of the six complementary-determining regions 
(CDRs) of both VL and VH with a hidden area of approximately 1.856 A˚ 2. However, the binding to hPD-L1 is 
dominated by the VH of avelumab by all three CDR loops and VL contributes with partial contacts by CDR1 and 
CDR3 loops, allowing VL CDR2 devoid of binding to hPD-L1. Further analysis based on structural superposition 
between the human PD1 (hP1)/h(PD-L1) complex and the avelumab-single-chain Fv fragment/Hpd-L1 complex 
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showed that the avelumab-binding epitope region on hPD-L1 overlapped with the hPD1-binding region; this 
result suggests that the binding of avelumab with hPD-L1 can prevent the binding of hPD1 to hPD-L1 [35] 
 
Pharmacodynamics 
The PD-1 & PD-L1 axis 
The Pd-1 gene was initially isolated in 1992 by Ishida et al. using the subtractive hybridization technique and 
classified it in the immunoglobulin gene superfamily [36]. PD-1 is a T-cell immune checkpoint receptor that has 
been detected on B-cells, activated monocytes, dendritic cells (DCs) and NK cells and NK T-cells [37]. 
The molecule is composed of an extracellular IgV domain and an intracellular domain with buried phosphory- 
lation sites placed on an immune receptor inhibitory tyrosine-based switch motif and an immune tyrosine-based 
inhibitory motif [38]. Immune tyrosine-based inhibitory motif and immune receptor inhibitory tyrosine-based 
switch motif tether the inhibitory phosphatase SHP-2 [39] and the former motif is required for the inhibitory 
activity of PD-1 on active T-cells [40]. 
PD-1 has shown to decrease the activity of tumor-infiltrating lymphocytes in cancer [20] and can bind to PD-L1 
(B7-H1/CD274) and PD-L2 (B7-DC/CD273), which promotes T-cell anergy through the interaction with the 
former receptor [41]. Therefore, only the interaction between PD-L1 and PD1 promotes T-cell anergy. Successively, 
after the interaction between PD-L1 and PD-1, the receptor becomes inactivated. Therefore, PD-1 is a negative 
regulator of antitumor T-cell effector activity [42]. 
PD-L1 plays a pivotal role in self-tolerance, safeguarding peripheral tissues from autoimmune diseases and 
inflammation [43]. 
PD-L1 is classified as a type I transmembrane protein that consists of intracellular domains, transmembrane and 
extracellular domains (IgV-like domain, IgC-like domain, signal sequence) and shares 37% sequence homology 
with PD-L2 [44,45]. In addition, PD-L1 has been reported to be expressed on B-cells, T-cells, macrophages, 
DCs, pancreatic islet cells, vascular endothelial cells, lung, heart, liver and placenta [38]. While PD-L1 is mainly 
expressed on the surface of somatic cells following the exposure to proinflammatory cytokines [46], the PD-L2 
expression is more restricted to APCs [46]. Several proinflammatory cytokines, such as IL-10, TNF-α, INF-γ, 
GM-CSF and VEGF, promote PD-L1 expression. PD-L1 expression caused by inflammatory cytokines in the 
tumor microenvironment leads to a PD-1-mediated T-cell exhaustion, thereby inhibiting the antitumor cytotoxic 
T-cell response [47,48]. 
 
PD-1 & PD-L1 pathway in the context of cancer 
By binding its ligands, PD-1 acts as immune checkpoint under normal conditions and plays a pivotal role in 
silencing the immune system with the suppression of T-cells and upregulating Treg, which in turn decreases 
autoimmunity and enhances self-tolerance [49,50]. Once engaged with PD-L1 or PD-L2, the tyrosine phosphatases 
recruitment will start, leading to the blockade of the downstream activity of PI3K/Akt pathway with an inhibitory 
signal, and thereby to the cell cycle interruption and the T-cell activation [40,51]. 
A wide range of tumors such as renal cell cancer, multiple myeloma, leukemia, GC, bladder cancer, cutaneous 
cancer, hepatocellular cancer, glioblastoma, melanoma and breast cancer, as well as non-small-cell lung cancer show 
PD-L1 expression [52,53], whereas PD-1 has been notably observed on tumor-infiltrating lymphocytes [54]. Cancer 
cells begin to overexpress PD-L1 and PD-L2 for lowering T-cells efficiency when are attacked by the immune 
system; as a consequence, T-cells are silenced leading to immune escape [53]. Furthermore, by upregulation of 
PTEN along with the downregulation of mTOR, ERK2, S6 and phospho-Akt, PD-L1 can promote Treg cell 
development. Consequentially, PD-L1 will suppress the activation of T-cells as a result of the formation and the 
holding of Tregs [55]. Contrarly, Dong et al. have reported that PD1 suppress PI3K-mediated cell death in activated 
T-cells, leading to the downregulation of Bcl-xL and antiapoptotic proteins [41]. 
Furthermore, PD-1 can also suppress the T-cell receptor (TCR) acting on the inhibitory function provided by 
the tyrosine phosphatase SHP-2, which mediates dephosphorylation of signaling molecules downstream of the 
TCR [46], which is needed for the release of the stimulatory IL-2 factor, thereby making way for the cell cycle 
blockade and the suppression of T-cell proliferation [56]. 
 
Checkpoint inhibitors 
A large number of genetic and epigenetic modifications of all cancers provide a various range of antigens that 
our immune system uses to recognize as ‘self ’ or as ‘non-self ’. The capacity of T-cells to drive several immune 
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Figure 1.  Mechanism of action of avelumab in the programmed death-1/programmed death ligand-1 pathway for 
the treatment of gastric cancer. 
 
 
responses (by CD4+ helper T-cells), identify and eliminate antigen-expressing cells (by CD8+ effector T-cells) and 
distinguish peptides from all cellular compartments has made them an interesting target to pursue in order to tailor 
the endogenous immune system against cancer [57]. T-cell response is initiated with the TCR antigen recognition 
and it is regulated by immune checkpoints, which play a pivotal role in immune homeostasis maintenance [53,58]. 
Unrestrained immune response to pathogens or mutated/overexpressed self-antigens can cause tissue damages and 
autoimmune diseases. Immune checkpoints consist of costimulatory and inhibitory signals, enhancing the immune 
response when appropriate, but suppressing it to prevent tissue damages. 
Tumors can activate inhibitory immune checkpoint in order to suppress the immune response to tumor. 
Therefore, the immunotherapy plans to block the suppressive immune checkpoint to re-establish the immune 
response against cancer (Figure 1) [59]. 
Several inhibitory intracellular signals are initiated through membrane receptors and their ligands are either 
membrane-bound or soluble cytokines. It has been shown that the overexpression of checkpoint inhibitors are 
found to be overexpressed in the tumor microenvironment rather than in cancer and normal tissue [48]. 
 
ADCC of avelumab 
ADCC is a well-established mechanism of action for some currently used antitumoral antibodies, such as rituximab, 
cetuximab and trastuzumab [60]. Matching ADCC-promoting agents and tumor-targeting monoclonal antibodies 
(mABs) that encourage effector cells might lead to a great clinical benefit. However, engineered anti-PD-L1 IgG1 
(e.g., durvalumab or atezolizumab) and anti-PD1 IgG4 antibodies (e.g., pembrolizumab or nivolumab) have been 
developed with a low ADCC activity, based upon a hypothetical potential of ADCC to eliminate activated T- 
cells [61,62]. Nevertheless, in preclinical and clinical studies, avelumab did not show any remarkable effect on the 
number of circulating PD-L1 immune cells or on patients’ total lymphocyte count, suggesting that none immune cell 
subset is measurably depleted by avelumab treatment [30,63]. Thus, avelumab is the exclusive therapeutic antibody, 
which may exploit ADCC-mediated lysis of cancer cells and immune checkpoint inhibition simultaneously. 
 
Pharmacokinetics & metabolism 
Avelumab pharmacokinetics was assessed in patients affected by different solid tumors at doses swinging from 1 
to 20 mg/kg every 2 weeks [65]. Patients who received 10 mg/kg had the mean volume of distribution at steady 
state of 4.72 l. Avelumab is primarily eliminated through proteolytic degradation and the circulating half-life was 
evaluated to be approximately 6 days, peculiarly shorter compared with the other monoclonal antibodies, possibly 
because of its high isoelectric point (8.9–9.3) that can raise drug uptake, distribution and clearance [66]. Forty-eight 
hours after avelumab infusion, immune cytokine responses were evident in some patients with a notable increase 
in IL-6, TNF-α and IFN-γ [66]. A dose of 10 mg/kg every 2 weeks was chosen for further developments on target 
occupancy and drug pharmacokinetics, since no maximum tolerated dose was identified [66]. 
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Clinical efficacy 
Phase I/Ib clinical trials 
The PD-L1 inhibitor avelumab has been initially tested in two studies made of GC\GEJC patients. A Phase Ib 
clinical test named JAVELIN Solid Tumor trial, made of 150 patients without (1 L-mn) or with (2 L) disease 
progression, with locally advanced or metastatic GC\GEJC received second-line avelumab (10 mg/kg every 2 
weeks) independently from the expression of PD-L1. In the 1 L-mn and 2 L subgroups, median duration of 
response corresponded to 21.4 months (95% CI: 4.0–NA) and 3.5 months (95% CI: 2.8–8.3) and disease 
control rates were of 56.7 and 28.3%, respectively. Median progression-free survival (PFS) in 1 L-mn and 2 L 
subgroups were 2.8 months (95% CI: 2.3–4.1) and 1.4 months (95% CI: 1.3–1.5) and overall survival (OS) 
of 11.1 months (95% CI: 8.9–13.7) and 6.6 months (95% CI: 5.4–9.4), respectively. The confirmed objective 
response rate (ORR) was 6.7% (n = 6; 95% CI: 2.5–13.9%) and the disease control rate was 28.3% [67]. A Phase 
I expansion cohort in Japanese patients has been investigating avelumab in patients with advanced GC\GEJC 
progressing to chemotherapy (JAVELIN Solid Tumour JPN) [68]. Among 21 heavily pretreated patients enrolled 
in the dose-expansion cohort, the ORR was 10% (95% CI: 2.8–23.7) and median OS was 9.1 months (95% CI: 
7.2–11.2). 
 
Phase III & ongoing clinical trials 
A randomized Phase III clinical trial called JAVELIN Gastric 300 (NCT02625623) has been comparing the use 
of third-line avelumab versus chemotherapy. This clinical investigation was a randomized, multicenter, open-label, 
Phase III study constituted of 371 patients with advanced GC/GEJC who progressed to two lines of therapy, 
who were not selected for PD-L1 expression. All the patients received best supportive care (BSC) as background 
therapy and were stratified according to a geographic region (Asia vs non-Asia). However, this study did not meet 
its primary end point of improving OS, with a median OS of 4.6 versus 5.0 months (hazard ratio [HR]: 1.1 [95% 
CI: 0.9–1.4]; p = 0.81) in avelumab versus chemotherapy arms. Neither the secondary end points were met for 
PFS, with a median PFS of 1.4 versus 2.7 months (HR: 1.73 [95% CI: 1.4–2.2]; p > 0.99) nor for ORR, with an 
ORR of 2.2% in avelumab (n = 4; 95% CI: 0.6–5.4) versus the 4.3% (n = 8; 95% CI: 1.9–8.3) [69]. 
Another randomized, Phase III clinical trial made of 499 patients with GC/GEJ patients, named JAVELIN 
Gastric 100 (NCT02625610), has been testing the efficacy of switch-maintenance treatment. This study has been 
comparing avelumab versus continuation of capecitabine + oxaliplatin (XELOX) or leucovorin + 5-fluorouracil (5- 
FU) + oxaliplatin (FOLFOX) in patients with advanced GC/GEJC who did not progress to first-line chemotherapy. 
The aim of this clinical trial is to test whether avelumab can provide durable antitumor activity after tumor shrinkage 
and immunogenic priming obtained because of first-line chemotherapy, with less tumor toxicity burden because of 
the additional chemotherapy. The primary end point is to demonstrate the superiority of avelumab maintenance 
therapy compared with continuation of 1 L chemotherapy in terms of OS in all randomized or PD-L1-positive 
tumor-bearing patients. Secondary objectives include the demonstration of the superiority of avelumab versus 
continuation of 1 L chemotherapy in terms of PFS, ORR, safety and tolerability and quality of life [70]. Table 1 
summarizes all the ongoing clinical trials testing avelumab in GC/GEJC patients. 
 
Safety & tolerability 
Avelumab is considered to be well tolerated according to the results of Phase I and II JAVELIN trials. As to the safety 
results of the use of avelumab from the JAVELIN phase Ib clinical trial, 17 of the patients in the dose escalation 
receiving avelumab did not have a dose-limiting toxicity and the maximum tolerated dose was not reached. Of the 
40 patients enrolled in the dose-expansion part, 21 (52.4%) received ≥3 prior lines of therapy for the advanced 
disease; three of the 40 patients (7.5%) had grade 3 treatment-related adverse events (AEs) (hyponatremia, alanine 
aminotransferase increase and anemia) and no grade ≥4 treatment related AEs. Five of the patients (12.5%) had 
immune-related AE all grade 1 or 2. Therefore, avelumab had a relatively safe profile in the Japanese population 
with advanced GC [68]. Data from the JAVELIN II, multicenter, open-label, single-arm, Phase II trial showed 
that in the 1738 GC patients, grade ≥3 treatment-related adverse events (TRAEs) occurred in 177 (10.2%). The 
most common adverse events were fatigue (in 17 patients; 1.0%) and infusion-related reactions (in ten patients; 
0.6%). TRAE leads to discontinuation in 107 patients (6.2%) and death in four patients (0.2%). Grade ≥3 
immune-related adverse events (irAEs) occurred in 39 patients (2.2%) leading to discontinuation in 34 patients 
(2.0%). Moreover, avelumab is well tolerated with a manageable safety profile [71]. 
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Table 1.  Selected ongoing trials with avelumab in gastric cancer. 
Clinical trial Study design Intervention/s Setting Primary end Phase Status 
identifier    point   
NCT03399071 40 participants, parallel FLOT + avelumab First-line pCR II Recruiting 
 assignment, open label      
NCT02625610 499 participants, parallel 
assignment, open label 
Avelumab maintenance or 
continuation of first-line 
chemotherapy oxaliplatin–
fluoropyrimidine doublet 
after induction with 
First-line 
maintenance 
OS III Active, not 
recruiting 
NCT01943461 57 participants, single group Avelumab (dose escalation) First-line DLT I Active, not 
 assignment, open label     recruiting 
NCT03475953 212 patients, nonrandomized, 
single group assignment 
Avelumab and regorafenib Second-line Phase I: RPF2D 
Phase II: 
assessment of 
antitumor 
activity 
I/II Recruiting 
NCT02554812 560 patients, randomized, parallel      Avelumab + utomilumab or 
assignment, open label PF-04518600 or PD0360324 or 
utomilumab + PF-04518600 
Second-line DLT II Recruiting 
NCT03288350 55 patients, single group mDCF + avelumab Perioperative pCR II Recruiting 
 assignment, open label     
NCT03783936 63 participants mFOLFOX6 + trastuzumab + First-line bORR II Not yet recruiting 
 Intervention model: avelumab     
 single group assignment, open     
 label     
bORR: Best objective response rate; DLT: Dose-limiting toxicity; OS: Overall survival; pCR: Pathological complete response; RPF2D: Recommended Phase II dose. 
 
Regulatory affairs 
On 23rd March 2017, avelumab received the FDA approval for the treatment of metastatic Merkel cell carcinoma 
as a monotherapy in patients aged more than 12 years in the US and in Europe [72]. On May 2017, avelumab 
received the approval for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed 
during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum- 
containing chemotherapy. Avelumab is administrated intravenously with a dose of 10 mg/kg over 60 min every 
2 weeks [73]. Patients must undergo prior medication with antihistamine and acetaminophen to prevent infusion 
reactions for the first four treatments and afterward if necessary [74]. 
 
Conclusion 
The stomach is susceptible to infections that trigger T-cell signaling and response leading to cancer. In fact, 
Capitani et al. showed that HP1454, a Gram-negative bacterium triggered T-cell antigen receptor-dependent 
signaling, Th1/Th17 inflammatory responses and lymphocyte proliferation and CXCL12-dependent cell adhesion 
and migration [75]. This shows how the stomach’ environment is already used to mechanisms triggering the immune 
system and using a drug modulating such system could be a good auxiliary approach to conventional drugs. 
Avelumab is the most recent anti-PD-L1 antibody efficient for the Merkel cell carcinoma as it has reached FDA 
approval for the treatment of this disease. Despite the negative results obtained for avelumab versus chemotherapy 
from the Phase III clinical trial made of 371 GC patients, termed JAVELIN Gastric 300, the results from another 
Phase III clinical trial made of 499 patients, named JAVELIN Gastric 100, experimenting avelumab maintenance 
therapy versus continuation of chemotherapy could still demonstrate the survival efficacy of this recently developed 
monoclonal anti-PD-L1 therapy that had demonstrated its capacity of eliciting clinical responses and safety profiles 
in early phase clinical trials. 
Moreover, there are other immune checkpoint inhibitors that have been tested in Phase III clinical trials for 
GC/GEJC. CheckMate 649 (NCT02872116) is a Phase III trial that has been comparing nivolumab plus ipili- 
mumab arm versus nivolumab plus investigator choice of chemotherapy (folfox or xelos) arm versus chemotherapy 
alone arm. ATTRACTION 4 (NCT02746796) is a Phase II/III trial evaluating nivolumab plus chemotherapy 
(oxaliplatin plus either capecitabine or S-1) arm versus chemotherapy alone arm in Asian patients. KEYNOTE-062 
(NCT02494583) is a Phase III clinical trial comparing pembrolizumab arm or pembrolizumab and cisplatinum/5- 
FU (or capecitabine) arm versus cisplatin/5-FU alone arm for treating PD-L1-positive GC/GEJC patients. 
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The results from the ongoing clinical trials testing avelumab and other immunotherapies are eagerly awaited 
to evaluate the capacity of checkpoint inhibitors to improve advanced GC/GEJC clinical outcomes. Of note, 
as an alternative strategy the checkpoint inhibitor could be used in combination with stimulators of T-cells’ 
receptors. For example, nivolumab and/or ipilimumab have been tested for advanced GC/GEJC (NCT03126110) 
in combination with INCAGN91876 (anti-glucocorticoid-induced tumor necrosis factor receptor-related protein) 
versus ipilimumab alone. 
Moreover, there is a need in future to have accurate predictive biomarkers that could help clinicians to decide 
whether patients would best respond or not to checkpoint inhibitors. Since in a large cohort of 2220 lung cancer 
patients in a Phase III, multicenter, open-label study showed that patients respond better to checkpoint inhibitors 
when they have a high tumor burden, even better than in patients with high PD-L1 [76], it might be interesting in 
future to test tumor burden as a predicting biomarker for the efficacy of immunotherapy in GC/GEJC. 
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